Skip to main content
BioForge

SPPS vs fermentation

A head-to-head comparison of solid-phase peptide synthesis and fermentation-based manufacturing for peptide therapeutics.

BioForge→SPPS vs Fermentation

Solid-phase peptide synthesis (SPPS) has been the dominant method for peptide manufacturing for over 60 years. It is also reaching its limits. Constructive.bio’s BioForge platform replaces SPPS with E. coli fermentation, manufacturing peptides containing up to 3 different non-canonical amino acids per molecule at scales from milligrams to kilograms — without the solvent waste, sequence length constraints, or escalating costs that define chemical synthesis.

SPPS — Chemical synthesis

Peptide chain anchored to polystyrene or PEG resin via acid-labile linker.
Fmoc removal using 20% piperidine in DMF. ~15 minutes per cycle.
Activated amino acid coupling. Requires 2–5× molar excess. 30–60 minutes per residue.
Multiple washes with DMF and DCM between each step. Primary source of solvent consumption.
Preparative reverse-phase HPLC. Energy-intensive. Separates target peptide from deletion/truncation impurities.
Solvents: DMF, DCM, NMP·Yield drops with each cycle

Fermentation — Biological synthesis

Peptide sequence encoded in plasmid or genome. ncAA positions specified by reassigned codons.
Syn61-derived genome-recoded strain. Freed codons reassigned to non-canonical amino acids.
Standard E. coli fermentation in aqueous media. 24–48 hours. Scalable in standard bioreactors.
Chromatographic purification. Lower impurity burden than SPPS due to ribosomal fidelity.
Full-length peptide with ncAAs at defined positions. Consistent across batches.
Aqueous media·Consistent yield — no per-residue loss
Hover or tap each step for details. SPPS requires repeated solvent-intensive coupling cycles. Fermentation encodes the full sequence in DNA and produces the peptide in a single biological step.

Two Approaches, Fundamentally Different

SPPS builds peptides from the C-terminus, coupling one amino acid at a time to a solid resin support. Each coupling cycle requires activation, deprotection, and washing steps using organic solvents — primarily DMF, NMP, and DCM. Yields decrease with each cycle: a 30-residue peptide at 99% per-step efficiency yields only 74% full-length product; at 40 residues, this drops to 67%. Beyond 50 amino acids, crude yields are typically too low for practical manufacturing. Each non-canonical amino acid requires a bespoke Fmoc-protected monomer, developed over weeks to months.

Fermentation-based manufacturing encodes the entire peptide sequence in DNA, expressed in genome-recoded E. coli (Syn61-derived strains) where specific codons have been freed and reassigned to non-canonical amino acids. The ribosome builds the peptide in a single step, incorporating standard and non-canonical amino acids alike. There is no per-residue yield loss, no sequence length constraint, and no bespoke monomer synthesis. Production uses standard bioreactor infrastructure — stainless steel fermenters available at contract manufacturers worldwide.

Head-to-Head Comparison

SPPSPractical limit ~50 amino acids. Yields drop sharply beyond 30–40 residues.
Fermentation (BioForge)No inherent length limit. Peptides and proteins of any length.
At 99% per-step coupling efficiency, a 30-residue SPPS synthesis yields 74% full-length product. At 40 residues: 67%. At 50 residues: 61%. Fermentation fidelity is determined by ribosomal translation, which is consistent regardless of peptide length.
SPPSLimited by monomer chemistry. Each ncAA requires bespoke protected building block. Typically 1 ncAA per peptide.
Fermentation (BioForge)Up to 3 different ncAAs per molecule, with multiple instances of each, genetically encoded at defined positions.
Each non-canonical amino acid in SPPS requires synthesis of a custom Fmoc-protected monomer — typically 4–12 weeks of development and £10,000–50,000+ per monomer. BioForge uses engineered tRNA/synthetase pairs to incorporate ncAAs during translation, with the same cellular machinery regardless of ncAA type.
SPPSLinear cost scaling. Doubling output roughly doubles solvent, resin, and reagent consumption.
Fermentation (BioForge)Fermentation economics. Scales from mg to kg on standard bioreactor infrastructure. Non-linear cost curve.
A typical SPPS manufacturing campaign for a 40-residue GLP-1 analogue at kilogram scale requires approximately 10,000–15,000 litres of organic solvent. Fermentation at equivalent scale uses aqueous media in standard bioreactors, with sub-linear cost scaling as batch size increases.
SPPSWeeks to months to synthesise each new protected ncAA monomer.
Fermentation (BioForge)New ncAAs onboarded through genetic encoding. No bespoke monomer synthesis.
Developing a new Fmoc-ncAA monomer for SPPS involves organic synthesis, protection group chemistry, and coupling optimisation. BioForge onboards new ncAAs by engineering aminoacyl-tRNA synthetases — a biological optimisation process that leverages the platform’s existing genetic code expansion infrastructure.
SPPSDeletion and truncation impurities accumulate with length. Extensive HPLC purification required.
Fermentation (BioForge)Genetically encoded — ribosome builds sequence as specified by DNA. High fidelity by design.
SPPS crude purity for a 30-residue peptide is typically 60–80%, with the balance being deletion sequences, truncations, and racemisation products. Ribosomal translation has an error rate of approximately 1 in 3,000 per codon, giving >99% fidelity for peptides of any practical length.
SPPSLimited to α-amino acids unless specialised chemistries used.
Fermentation (BioForge)α-amino acids, α,α-disubstituted, β-amino acids accessible through genetic code expansion.
SPPS can incorporate β-amino acids and other non-standard backbones, but each requires specialised coupling conditions and often reduced yields. Genetic code expansion accesses these backbone chemistries through the same ribosomal machinery used for standard amino acids.
SPPSVariability increases with sequence complexity.
Fermentation (BioForge)Genetically encoded process delivers consistent product across batches.
SPPS batch-to-batch variability is driven by coupling efficiency fluctuations, resin quality, and environmental conditions during multi-day synthesis campaigns. Fermentation consistency is determined by the genetic template — the same DNA produces the same peptide.
SPPSDedicated peptide synthesis facilities. Specialised equipment.
Fermentation (BioForge)Standard E. coli fermentation. Widely available globally.
Global SPPS manufacturing capacity is concentrated in a relatively small number of specialised facilities. E. coli fermentation capacity exists at hundreds of contract manufacturing sites worldwide, with established regulatory frameworks for biologics production.
SPPSN/A
Fermentation (BioForge)Syn61-derived strains inherently resistant to bacteriophage infection.
Bacteriophage contamination is a significant risk in industrial E. coli fermentation, capable of destroying entire production batches. Syn61-derived strains used by Constructive.bio have a fundamentally recoded genome that phages cannot hijack, providing inherent resistance without requiring additional containment measures.

The Cost Equation

Cost per gramProduction volumeStrain engineeringSub-linear scalingScale advantageSPPSFermentationFermentation advantage widens. Sub-linear scaling.SPPSFermentation (BioForge)SPPS competitive at small scale, simple sequences. Crossover — fermentation economics take over. Fermentation advantage widens. Sub-linear scaling. At low production volumes, SPPS has lower cost per gram. At high production volumes, fermentation achieves significant cost advantage through sub-linear scaling.SPPS competitive at small scale, simple sequencesCrossover — fermentation economics take overFermentation advantage widens. Sub-linear scaling.SPPS cost per gram is roughly constant regardless of volume. Fermentation cost per gram starts higher due to strain engineering but drops steeply, crossing below SPPS and continuing to decrease at scale.Fermentation: ~27% lower cost at scale

SPPS costs scale linearly with peptide length and production volume. Each additional amino acid residue requires reagents, solvent, and time. Doubling output doubles solvent consumption, resin usage, and purification burden. For a 40-residue peptide at multi-kilogram scale, raw material costs alone — Fmoc-protected amino acids, coupling reagents, cleavage cocktails — represent a significant fraction of cost of goods.

Fermentation economics are fundamentally different. The cost of encoding a peptide sequence in DNA is independent of length. Fermentation runs consume glucose, salts, and water — commodity inputs. Increasing production volume means larger or additional fermentation runs, but the per-unit cost decreases as fixed infrastructure costs are amortised. The cost curve is sub-linear: doubling output does not double cost.

For ncAA-containing peptides, the gap widens further. SPPS requires bespoke Fmoc-protected monomers for each non-canonical amino acid — synthesis that can take months and cost tens of thousands of pounds per monomer. Fermentation uses the same translation machinery regardless of ncAA type: the cost of incorporating one ncAA, two ncAAs, or three ncAAs in a single peptide is essentially the same.

The Scale Challenge

$48B

Peptide market today

$100B+

Projected by 2030

The global peptide therapeutics market is valued at approximately $48 billion and projected to exceed $100 billion by 2030. GLP-1 receptor agonists alone are expected to require tens of tonnes of active ingredient annually — volumes that would consume the entire global SPPS manufacturing capacity multiple times over. The industry faces a structural manufacturing bottleneck that incremental improvements to SPPS cannot resolve.

BioForge addresses this directly. Fermentation uses the same stainless steel bioreactor infrastructure used for monoclonal antibody and recombinant protein production — installed capacity that already exists at scale globally. Constructive.bio does not require new manufacturing facilities. The platform runs on existing infrastructure, at existing contract manufacturers, with established regulatory frameworks for biologics manufacturing.

Frequently Asked Questions

How does fermentation-based peptide manufacturing compare to SPPS?

Fermentation uses genome-recoded E. coli, encoding the peptide sequence in DNA rather than building it chemically step by step. This removes sequence length constraints, enables incorporation of multiple non-canonical amino acids per molecule, and scales on standard bioreactor infrastructure. SPPS remains effective for short, simple peptides at small scale, but faces structural limitations for complex ncAA-containing peptides at manufacturing volumes.

Can fermentation produce peptides with non-canonical amino acids?

Yes. Constructive.bio’s BioForge platform incorporates up to 3 different ncAAs per molecule, with multiple instances of each, at genetically defined positions. This is achieved through genetic code expansion — reassigning codons freed by genome recoding in Syn61-derived strains. Each ncAA is incorporated by the ribosome during translation, not added post-translationally.

What are the limitations of SPPS for modern peptide therapeutics?

SPPS faces three structural challenges: (1) yields decrease exponentially with peptide length, with a practical limit of approximately 50 amino acids; (2) each non-canonical amino acid requires a bespoke Fmoc-protected monomer, adding months of development per new chemistry; (3) cost, solvent consumption, and waste scale linearly with production volume, making multi-tonne manufacturing economically and environmentally challenging.

Is fermentation-based peptide manufacturing scalable?

Yes. Fermentation uses standard E. coli bioreactor infrastructure that is widely available globally. Production scales from milligrams to kilograms on the same platform, with sub-linear cost scaling — doubling output does not double resource consumption. This contrasts with SPPS, where costs scale roughly linearly with volume.

How does BioForge ensure peptide sequence fidelity?

The peptide sequence is genetically encoded in DNA, and the ribosome builds the molecule to template with high fidelity. This is fundamentally different from SPPS, where deletion and truncation impurities accumulate with each coupling cycle, requiring extensive HPLC purification to isolate the correct product.

Explore how BioForge can replace SPPS in your pipeline

Discuss partnership →
← Back to BioForgeSustainability →